Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D09AFJ
|
||||
Former ID |
DIB016340
|
||||
Drug Name |
SR-121787
|
||||
Synonyms |
SR-121566; SR-121566a
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Thrombosis [ICD9: 437.6, 453, 671.5, 671.9; ICD10:I80-I82] | Discontinued in Phase 2 | [546615] | ||
Company |
Sanofi-Synthelabo
|
||||
Structure |
Download2D MOL |
||||
Formula |
C27H37N5O6S
|
||||
Canonical SMILES |
c1(nc(cs1)c1ccc(/C(=N/C(=O)OCC)/N)cc1)N(CCC(=O)OCC)C1CC<br />N(CC(=O)OCC)CC1
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Glycoprotein IIb/IIIa receptor | Target Info | Modulator | ||
Reactome | Platelet degranulation | ||||
Elastic fibre formation | |||||
PECAM1 interactions | |||||
Molecules associated with elastic fibres | |||||
Integrin cell surface interactions | |||||
Syndecan interactions | |||||
ECM proteoglycans | |||||
Integrin alphaIIb beta3 signaling | |||||
GRB2:SOS provides linkage to MAPK signaling for Integrins | |||||
p130Cas linkage to MAPK signaling for integrins | |||||
VEGFA-VEGFR2 Pathway | |||||
MAP2K and MAPK activation | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.